Education and Training

Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Enroll-HD is a longitudinal, observational, multinational study that will integrate two existing Huntington's Disease (HD) registries, REGISTRY in Europe and COHORT in North America and Australia, while also expanding to include sites in Latin America and Asia. With no end date and annual assessments, the goal of Enroll-HD is to build a large and rich database of longitudinal clinical information and biospecimens. This database will serve as a basis for future studies aimed at developing tools and biomarkers for progression and prognosis, identifying clinically relevant phenotypic characteristics, and establishing clearly defined endpoints for interventional studies.

Stanford is currently not accepting patients for this trial.

Eligibility


Inclusion Criteria:

   - Carriers: This group comprises the primary study population and consists of
   individuals who carry the HD gene expansion mutation.

   - Controls: This group comprises the comparator study population and consists of
   individuals who do not carry the HD expansion mutation.

These two major categories can be further subdivided into six different subgroups of
eligible individuals:

   - Manifest/Motor-manifest HD: Carriers with clinical features that are regarded in the
   opinion of the investigator as diagnostic of HD.

   - Pre-Manifest/-Motor-manifest HD: Carriers without clinical features regarded as
   diagnostic of HD.

   - Genotype Unknown: This group includes a first or second degree relative (i.e., related
   by blood to a carrier) who has not undergone predictive testing for HD and therefore
   has an undetermined carrier status.

   - Genotype Negative: This group includes a first or second degree relative (i.e.,
   related by blood to a carrier) who has undergone predictive testing for HD and is
   known not to carry the HD expansion mutation.

   - Family Control: Family members or individuals not related by blood to carriers (e.g.,
   spouses, partners, caregivers).

   - Community Controls: Individuals unrelated to HD carriers who did not grow up in a
   family affected by HD. Data collected from community controls will be used for
   generation of normative data for sub-studies.

Participant status will be captured in the study database using 2 variables: 1)
Investigator Determined Status: this will be based on clinical signs and symptoms and
genotyping performed as part of medical care, and will be updated at every visit; and 2)
Research Genotyping Status: this will be based on genotyping conducted as part of Enroll-HD
study procedures. Based on research genotyping, participants will be reclassified under
this variable from Genotype Unknown to 'Carriers' or 'Controls'. Investigators and
participants will be blinded to this reclassification.

Exclusion Criteria:

   - Individuals who do not meet inclusion criteria,

   - Individuals with choreic movement disorders in the context of a negative test for the
   HD gene mutation.

   - For Community Controls: those individuals with a major central nervous system disorder
   will be excluded (e.g. stroke, Parkinson's disease, multiple sclerosis, etc.).

Participants under 18 may be eligible to participate (if they have juvenile-onset HD).

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Coburn
Not Recruiting